Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlmirallLBTSF 85 EV-to-EBITDA is 7.52 as of Jul. 18, 2026, which is 32% below its 10-year median of 11.00. GuruFocus rates LBTSF with a GF Score™ of 85/100 and a GF Value™ of $16.85. The stock has 4 warning signs investors should review. Among 741 Drug Manufacturers companies, Almirall ranks better than 73.28% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Almirall's enterprise value is $2,617 Mil.
Almirall's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $348 Mil. Therefore, Almirall's EV-to-EBITDA for today is 7.52.
The historical rank and industry rank for Almirall's EV-to-EBITDA or its related term are showing as below:
LBTSF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.03 Med: 11 Max: 79.87
Current: 8.1
During the past 13 years, the highest EV-to-EBITDA of Almirall was 79.87. The lowest was -20.03. And the median was 11.00.
LBTSF's EV-to-EBITDA is ranked better than 73.28% of 741
companies
in the Drug Manufacturers industry
Industry Median: 13.03
vs LBTSF: 8.10
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Almirall (OTCPK:LBTSF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Almirall's share price for today is $15.35.
Almirall's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.281.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Almirall's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Almirall's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Almirall EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Almirall's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Almirall's EV-to-EBITDA falls into.
Almirall's current Enterprise Value is $2,617 Mil.
Almirall's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $348 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Almirall (LBTSF) has a EV-to-EBITDA of 7.52 as of Jul. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Almirall. This is 32% below median its historical median of 11.00. According to the industry distribution chart, Almirall ranks #198 out of 741 companies in the Drug Manufacturers industry, placing it in the top 26.7%.
Is Almirall's EV-to-EBITDA too high?
Almirall's current EV-to-EBITDA of 7.52 is 32% below median its 10-year median of 11.00. The Drug Manufacturers industry median EV-to-EBITDA is 13.03. Almirall's value of 7.52 is 42.3% below this industry median. Based on the distribution chart, Almirall ranks #198 out of 741 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Almirall has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Almirall's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Almirall ranks #198 out of 741 companies for EV-to-EBITDA. This puts Almirall in the upper half of its industry. The industry median EV-to-EBITDA is 13.03. Almirall's value of 7.52 is 42.3% below this benchmark. While the company's 10-year median is 11.00 vs. the industry median of 13.03, Almirall has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.03, based on 741 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Almirall's current EV-to-EBITDA of 7.52 is 42.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Almirall. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Almirall's current EV-to-EBITDA is 7.52, which is 32% below median its own 10-year median of 11.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Almirall stock overvalued right now?
Almirall (LBTSF) has a current EV-to-EBITDA of 7.52. The stock's GF Value™ is $16.85, compared to a current price of $15.35 — trading 8.9% below its estimated fair value. The current EV-to-EBITDA is 7.52, which is 32% below median its 10-year median of 11.00 and 42.3% below the Drug Manufacturers industry median of 13.03. Almirall's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Almirall (LBTSF), the current EV-to-EBITDA is 7.52 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Almirall (LBTSF) Overvalued in 2026?
Based on GuruFocus' analysis, Almirall stock appears to be undervalued.
The current stock price of $15.35 is trading 8.9% below its estimated GF Value™ of $16.85.
Key valuation signals for LBTSF:
EV-to-EBITDA: 7.52 (32% below median its 10-year median of 11.00)
GF Value™: $16.85 vs. price of $15.35 (8.9% below fair value)
Industry Position: 42.3% below the Drug Manufacturers median (#198 of 741)
No single metric tells the full story. See the LBTSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Almirall SA is a skin-health focused pharmaceutical company based in Barcelona and the parent company of a group engaged in the purchase, manufacture, storage, marketing, and mediation in the sale of pharmaceutical specialities and products, as well as related raw materials. The Group applies science to provide medical solutions focused on skin health diseases and partners with healthcare professionals, and its activities also include cosmetics; chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food use; instruments and accessories for the chemical, pharmaceutical and clinical industry; and research on active chemical and pharmaceutical ingredients and products.
85GF Score
Get the complete analysis for LBTSF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LBTSF has been successfully added to your 
